Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes
- PMID: 27479247
- PMCID: PMC5118084
- DOI: 10.1001/jamainternmed.2016.1523
Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes
Erratum in
-
Missing Reference Citation.JAMA Intern Med. 2016 Oct 1;176(10):1579. doi: 10.1001/jamainternmed.2016.5900. JAMA Intern Med. 2016. PMID: 27695829 No abstract available.
Conflict of interest statement
Disclosures: Dr Butler is a member of the scientific advisory board for Semma Therapeutics. No other disclosures are reported.
Comment on
-
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.JAMA Intern Med. 2016 Oct 1;176(10):1474-1481. doi: 10.1001/jamainternmed.2016.1531. JAMA Intern Med. 2016. PMID: 27478902
-
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.JAMA Intern Med. 2016 Oct 1;176(10):1464-1473. doi: 10.1001/jamainternmed.2016.1522. JAMA Intern Med. 2016. PMID: 27479930
References
-
- Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14(1):1–4. - PubMed
-
- Garg T, Rosas U, Rivas H, Azagury D, Morton JM. National prevalence, causes, and risk factors for bariatric surgery readmissions. Am J Surg. 2016;212(1):76–80. - PubMed
-
- Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I. Adding liraglutide to a high-dose insulin regimen: a randomized, double-blind, placebo-control study [published online June 6, 2016] JAMA Intern Med - PubMed
-
- Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis [published online August 1, 2016] JAMA Intern Med - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
